AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2020
Mar 4, 2020
30604_dirs_2020-03-04_628df761-f3a1-42f7-9629-ee07004cf057.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-03-02
Reporting Person: HENDERSON MICHAEL THOMAS (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-03-02 | Common Stock | S | 2575 | $32.2012 | Disposed | 171712 | Direct |
| 2020-03-02 | Common Stock | S | 1400 | $32.8908 | Disposed | 170312 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019.
F2: Represents the weighted average sale price of the shares sold from $31.57 to $32.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.
F3: Represents the weighted average sale price of the shares sold from $32.65 to $33.21 per share.